Central Nervous System (CNS) Injury-Induced Immune Deficiency Syndrome (CIDS) is a significant cause of morbidity and mortality in patients with acute CNS injuries, such as stroke, traumatic brain injury (TBI), and spinal cord injury (SCI). CNS injury disrupts the normal balance between the immune system and the CNS, leading to secondary immunodeficiency and increased susceptibility to infections. This condition is a critical factor in poor recovery outcomes and is a model for studying brain control over immunity. Understanding CIDS is essential for developing effective therapeutic strategies to improve recovery after CNS damage. CIDS results from the CNS's altered response to systemic inflammation and injury, leading to immunosuppression and increased infection risk. The CNS senses inflammation through the autonomic nervous system and mounts an anti-inflammatory, immunodepressant response. However, in the absence of peripheral immune stimulation, this response can lead to profound immunosuppression, making the host vulnerable to infections. CIDS is associated with high infection rates, particularly pneumonia and sepsis, in patients with CNS injuries. Factors such as mechanical ventilation, aspiration, and impaired swallowing contribute to this risk. Infections after CNS injury are a major cause of mortality and poor outcomes, with pneumonia being the most common complication. CIDS involves both cell-mediated and humoral immune responses. CNS injury leads to reduced T-cell and NK-cell activity, impaired phagocytic function, and decreased cytokine production. These changes contribute to immunosuppression and increased infection risk. The sympathetic nervous system (SNS) and hypothalamic-pituitary-adrenal (HPA) axis play key roles in modulating immune responses, with SNS activation leading to immunosuppression. The neurogenic and humoral pathways are involved in CIDS. Damage to the CNS can lead to sympathetic outflow deafferentation, resulting in immunosuppression. The parasympathetic nervous system, particularly the vagus nerve, may also contribute to immune modulation through the cholinergic anti-inflammatory pathway. Therapeutic strategies for CIDS are limited, and further research is needed to understand the mechanisms and develop effective treatments. Monitoring immune parameters and managing infections are crucial in patients with CNS injuries. The role of the autonomic nervous system in CIDS remains an open question, with potential implications for immune function and recovery. Overall, CIDS is a complex condition that requires further investigation to improve outcomes in patients with CNS injuries.Central Nervous System (CNS) Injury-Induced Immune Deficiency Syndrome (CIDS) is a significant cause of morbidity and mortality in patients with acute CNS injuries, such as stroke, traumatic brain injury (TBI), and spinal cord injury (SCI). CNS injury disrupts the normal balance between the immune system and the CNS, leading to secondary immunodeficiency and increased susceptibility to infections. This condition is a critical factor in poor recovery outcomes and is a model for studying brain control over immunity. Understanding CIDS is essential for developing effective therapeutic strategies to improve recovery after CNS damage. CIDS results from the CNS's altered response to systemic inflammation and injury, leading to immunosuppression and increased infection risk. The CNS senses inflammation through the autonomic nervous system and mounts an anti-inflammatory, immunodepressant response. However, in the absence of peripheral immune stimulation, this response can lead to profound immunosuppression, making the host vulnerable to infections. CIDS is associated with high infection rates, particularly pneumonia and sepsis, in patients with CNS injuries. Factors such as mechanical ventilation, aspiration, and impaired swallowing contribute to this risk. Infections after CNS injury are a major cause of mortality and poor outcomes, with pneumonia being the most common complication. CIDS involves both cell-mediated and humoral immune responses. CNS injury leads to reduced T-cell and NK-cell activity, impaired phagocytic function, and decreased cytokine production. These changes contribute to immunosuppression and increased infection risk. The sympathetic nervous system (SNS) and hypothalamic-pituitary-adrenal (HPA) axis play key roles in modulating immune responses, with SNS activation leading to immunosuppression. The neurogenic and humoral pathways are involved in CIDS. Damage to the CNS can lead to sympathetic outflow deafferentation, resulting in immunosuppression. The parasympathetic nervous system, particularly the vagus nerve, may also contribute to immune modulation through the cholinergic anti-inflammatory pathway. Therapeutic strategies for CIDS are limited, and further research is needed to understand the mechanisms and develop effective treatments. Monitoring immune parameters and managing infections are crucial in patients with CNS injuries. The role of the autonomic nervous system in CIDS remains an open question, with potential implications for immune function and recovery. Overall, CIDS is a complex condition that requires further investigation to improve outcomes in patients with CNS injuries.